Acceleration of bone-marrow recovery by pre-treatment with cyclophosphamide in patients receiving high-dose melphalan

Lancet. 1978 Nov 4;2(8097):966-8. doi: 10.1016/s0140-6736(78)92529-1.

Abstract

7 patients with advanced malignant melanoma who were given cyclophosphamide (500 mg intravenously) 7 days before a high dose of melphalan (140 mg/m2) had a more rapid recovery of the peripheral white-cell count than did 4 patients who received melphalan alone. "Priming" by cyclophosphamide might be a practicable means of offsetting the bone-marrow toxicity of some chemotherapy regimens and it may permit higher doses of drugs to be given safely.

Publication types

  • Comparative Study

MeSH terms

  • Blood-Brain Barrier / drug effects
  • Bone Marrow / drug effects*
  • Bone Neoplasms / drug therapy*
  • Cyclophosphamide / administration & dosage*
  • Cyclophosphamide / toxicity
  • Drug Evaluation
  • Drug Therapy, Combination
  • Humans
  • Injections, Intravenous
  • Leukocyte Count
  • Leukocytes / drug effects
  • Melanoma / drug therapy*
  • Melphalan / administration & dosage*
  • Melphalan / toxicity
  • Neoplasm Metastasis
  • Premedication*
  • Skin Neoplasms / drug therapy*

Substances

  • Cyclophosphamide
  • Melphalan